Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges in interpreting the evidence for genetic predictors of ototoxicity.

Clinical pharmacology and therapeutics - 1 Dec 2013

Ratain M J, Cox N J, Henderson T O

Abstract excerpt

There has been recent controversy regarding predictors of cisplatin-induced ototoxicity in children, as highlighted in a previous issue of this journal. We have reviewed the two articles that purport to show an association between TPMT and COMT variants and ototoxicity, as well as the related patent applications dating back to 2006. We summarize statistical issues not fully addressed by the authors that appear to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Catechol O-Methyltransferase
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to TPMT gene

Share to Genetic Variation

Share to Hearing Loss

Share to Methyltransferases

Share to Multidrug Resistance-Associated Proteins

Source

Identifiers

PMID: 24241639
DOI: 10.1038/clpt.2013.178

Genes

COMT
TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges in interpreting the evidence for genetic predictors of ototoxicity.PMID 24241639Read ↗

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.Semantic proximity Read ↗

Pharmacogenomics of cisplatin-induced ototoxicity.Semantic proximity Read ↗

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.Semantic proximity Read ↗

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.Semantic proximity Read ↗

Genetic variants associated with cisplatin-induced ototoxicity.Semantic proximity Read ↗

Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients.Semantic proximity Read ↗

TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.Semantic proximity Read ↗

Otoprotection in Children Treated for Cancer: A CODEPEH Review Using PRISMA Methodology on Pharmacological Agents, Biomarkers and Genetic SusceptibilitySemantic proximity Read ↗

Genetic markers of cisplatin-induced hearing loss in children.Semantic proximity Read ↗

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.Semantic proximity Read ↗

Genetic risk factors of cisplatin induced ototoxicity in adult patients.Semantic proximity Read ↗

Systematic Review and Meta-Analysis of the Influence of Genetic Variation on Ototoxicity in Platinum-Based Chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.